ATR
| is a | gene |
| is | mentioned by |
| Full name | ATR serine/threonine kinase |
| EntrezGene | 545 |
| PheGenI | 545 |
| VariationViewer | 545 |
| ClinVar | ATR |
| GeneCards | ATR |
| dbSNP | 545 |
| Diseases | ATR |
| SADR | 545 |
| HugeNav | 545 |
| wikipedia | ATR |
| ATR | |
| gopubmed | ATR |
| EVS | ATR |
| HEFalMp | ATR |
| MyGene2 | ATR |
| 23andMe | ATR |
| UniProt | Q13535 |
| Ensembl | ENSG00000175054 |
| OMIM | 601215 |
| # SNPs | 23 |
| Max Magnitude | Chromosome position | Summary | |
|---|---|---|---|
| rs13091637 | 0 | 142,547,597 | |
| rs1802904 | 0 | 142,449,489 | |
| rs199731535 | 0 | 142,549,478 | |
| rs2227928 | 0 | 142,562,770 | |
| rs372271245 | 0 | 142,553,399 | |
| rs387906797 | 0 | 142,469,458 | |
| rs387907327 | 0 | 142,497,116 | |
| rs587776690 | 0 | 142,556,439 | |
| rs587777851 | 0 | 142,541,008 | |
| rs587777852 | 0 | 142,465,860 | |
| rs6782400 | 0 | 142,576,526 | |
| rs6805118 | 0 | 142,498,074 | |
| rs749753899 | 0 | 142,449,548 | |
| rs754030624 | 0 | 142,498,619 | |
| rs755272769 | 0 | 142,553,741 | |
| rs759554602 | 0 | 142,562,426 | |
| rs764800468 | 0 | 142,469,358 | |
| rs769216993 | 0 | 142,522,760 | |
| rs770800988 | 0 | 142,515,437 | |
| rs770869293 | 0 | 142,560,314 | |
| rs777982083 | 0 | 142,561,367 | |
| rs781260235 | 0 | 142,470,127 | |
| rs797045403 | 0 | 142,513,500 |
ATR, Serine/threonine-protein kinase, also known as rad3-related protein or FRAP-related protein, is a protein kinase involved in sensing DNA damage.
news "Women whose endometrial cancers have an ATR mutation have more than four times the risk of having their cancer return," study author Dr. Israel Zighelboim, a gynecologic oncologist, said in a news release from the university. "This and similar tumor biomarkers could potentially identify those patients most in danger of recurrence and guide the development of treatments aimed at these more aggressive tumors."
ATR mutations were found in about 5 percent of the 248 endometrioid endometrial tumor samples analyzed by the researchers. Women with ATR mutations were 4.29 times more likely to have the cancer recur after treatment and 3.88 times more likely to die.
The study appears online in the Journal of Clinical Oncology
